



# Trimel Pharmaceuticals

# Funding ahead of key drivers in H114

Trimel is raising C\$10.5m in equity (C\$0.711/share) following an 80% share price gain since the US regulatory pathway for CompleoTRT was resolved and agreement disputes with M&P were settled. Further potential returns in H114 will be geared towards the results of the Tefina Phase II ambulatory trial (Q214) and the FDA's decision (PDUFA date 28 May) on CompleoTRT.

## CompleoTRT dose and PDUFA date clarified

Trimel decided, following discussions with FDA officials, to focus its CompleoTRT (a testosterone replacement therapy) regulatory submission on a three-times daily (TID) dosing schedule. FDA officials had raised questions over the drug's ability to normalise testosterone in a Phase III study (n=306) when used twice-daily (BID), whereas the TID data were more robust. This pushed the PDUFA target action date back to 28 May 2014 (from 28 February), but in our view improves the product's likelihood of gaining approval. While a TID label could affect convenience vs current topical TR products (generally dosed once-daily), once CompleoTRT is approved, a process to extend the label to BID dosing could be initiated.

# Out-licensing deal likely to hinge on FDA decision

Added clarity on the CompleoTRT approval strategy should improve Trimel's prospects in partnering discussions, although we believe a transaction is more likely to occur after FDA approval (given de-risking benefits for a potential licensee).

# Tefina ambulatory study results in late Q214

Trimel recently completed recruitment for the 240-patient, 84-day Tefina ambulatory <a href="Phase II study">Phase II study</a> in anorgasmia/female orgasmic disorder (FOD). Positive results in Q214 could lead to partnership discussions and future trials. While there is little clarity on acceptable FDA endpoints for FOD, the FDA's recent guidance to Sprout Pharmaceuticals for a re-submission of a previously rejected FSD drug candidate, flibanserin, signals a potentially more flexible stance by the regulator on FSD drugs.

# Valuation: Recovering EV of C\$101m

Trimel's shares have now recovered the losses suffered in October 2013 when the FDA queried the CompleoTRT NDA. We estimate that after the capital raise and a US\$4.25m payment to M&P Patent to settle their legal disputes, current net cash (pro forma) is ~US\$17.5m. This should be sufficient to fund operations into Q414, and provide the flexibility to assess different out-licensing options for CompleoTRT.


Year end	Revenue (US\$m)	PBT (US\$m)	EPS (US\$)*	DPS (US\$)	P/E (x)	Yield (%)
12/11	0.0	(26.01)	(0.39)	0.0	N/A	N/A
12/12	0.0	(28.13)	(0.32)	0.0	N/A	N/A
12/13e	0.0	(28.60)	(0.23)	0.0	N/A	N/A
12/14e	5.12	(21.13)	(0.08)	0.0	N/A	N/A

### Pharma & biotech

21 February 2014



### Share price graph



Share details	
Code	TRL
Listing	TSX
Shares in issue	163.1m (post 14.8m private placement)

### **Business description**

Trimel Pharmaceuticals is a Canadian specialty pharmaceutical firm. Its lead products, CompleoTRT and Tefina, both deliver testosterone through a bioadhesive intranasal gel drug delivery platform for male hypogonadism and female sexual dysfunction (FSD)/female orgasmic disorder (FOD), respectively.

### Bull

- CompleoTRT different from competitors, may avoid a "black box" label warning.
- Tefina targets an area of high unmet need and has positive data from the VTS study.
- CompleoTRT Phase III study met FDA guidance for testosterone replacement (TR) therapy.

### Bear

- Uncertainty for CompleoTRT approval and timing given FDA concerns on BID-to-TID titration group and increasing scrutiny on long-term health risks (eg cardiovascular) associated with TR therapy.
- Financing likely required before year end 2014 unless CompleoTRT partnership deal is finalised.
- Uncertainty on acceptable endpoints by regulators for FSD/FOD.

# Analysts Pooya Hemami +1 646 653 7026 Christian Glennie +44 (0)20 3077 5727 Robin Davison +44 (0)20 3077 5737 healthcare@edisongroup.com

QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (<a href="https://www.fsa.gov.uk/register/firm/BasicDetails.do/sid=181584">www.fsa.gov.uk/register/firm/BasicDetails.do/sid=181584</a>). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. NZ is registered on the New Zealand Financial Services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [4608589] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. <a href="https://www.edisongroup.com">www.edisongroup.com</a>

### DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Trimel Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described he Investment Research and profit of the investment advised on the investment and such as and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US list not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corporationing state securities laws. As such, Edison US relies upon the "publishers' exclusion" from the definition of investment and wiser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corporationing state securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment and wiser under securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment and wiser under securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment to survey and an exclusion of provide great and the provided of the Investment and the provided from under the provided from the